v3.26.1
Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and development            
Total research and development expenses $ 16,057   $ 17,133   $ 36,040 $ 34,177
General and administrative            
Total general and administrative expenses 9,933   5,437   14,310 11,307
Total operating expenses 25,990   22,570   50,350 45,484
Other segment income 644   1,679   1,732 3,435
Income tax expense 0   283   0 283
Net loss (25,346) $ (23,272) (18,354) $ (21,158) (48,618) (39,512)
Reconciliation of profit or loss            
Consolidated net loss (25,346)   (18,354)   (48,618) (39,512)
Milestone Revenue            
Segment Reporting [Line Items]            
Revenues 0   2,820   0 2,820
Operating Segments            
Research and development            
Clinical product candidates 8,760   4,388   18,280 9,534
Clinical product manufacturing 1,409   6,194   5,159 9,578
Personnel-related expenses excluding stock-based compensation 3,973   3,490   8,531 8,229
Stock-based compensation 451   569   806 1,691
Depreciation and amortization 242   458   630 931
Other [1] 1,222   2,034   2,634 4,214
Total research and development expenses 16,057   17,133   36,040 34,177
General and administrative            
Personnel-related expenses excluding stock-based compensation 2,810   1,060   4,176 2,551
Stock-based compensation 5,077   2,446   5,932 4,955
Professional and consultant fees 976   863   2,028 1,677
Other [2] 1,070   1,068   2,174 2,124
Total general and administrative expenses 9,933   5,437   14,310 11,307
Total operating expenses 25,990   22,570   50,350 45,484
Other segment income [3] 644   1,679   1,732 3,435
Income tax expense 0   283   0 283
Net loss (25,346)   (18,354)   (48,618) (39,512)
Operating Segments | Milestone Revenue            
Segment Reporting [Line Items]            
Revenues $ 0   $ 2,820   $ 0 $ 2,820
[1] Other research and development segment items include facilities expenses, lab services, professional services and technology costs.
[2] Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.
[3] Other segment income for the three months ended June 30, 2026 and 2025 consisted of $0.3 million and $1.0 million of interest and investment income and $0.4 million and $0.7 million of sublease income, respectively. For the six months ended June 30, 2026 and 2025, other segment income consisted of $0.7 million and $2.2 million of interest and investment income and $1.0 million and $1.2 million of sublease income, respectively.